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ABSTRACT
Background Pneumonia among nursing home (NH)
residents has increased considerably in recent years, but
it remains unclear whether it should be considered as
community-acquired pneumonia (CAP) or a new category
of infection.
Methods 150 consecutive cases of NH-acquired
pneumonia (NHAP) (from 1 February 1997 to 1 July
2007) were analysed.
Results Patients (median age, 82 years; range,
77e87 years) showed numerous co-morbidities,
(neurological, 55%; pulmonary, 38%; cardiac, 35%) and
severe disability for daily activities (partial, 32%; total,
31%). Cases of NHAP were mainly classified as mild to
moderate according to the CRB-65 score (CRB-65
classes 0e1 and 2, 41% each). In-hospital and 30-day
mortality were 8.7% and 20%, respectively. Aetiology
was defined in 57 cases (38%). The most common
isolates were Streptococcus pneumoniae (58%),
Enterobacteriaceae (Gram-negative bacteria (GNB))
(9%), atypical bacteria (7%), respiratory viruses (5%),
methicillin-resistant Staphylococcus aureus (MRSA) (5%)
and Legionella pneumophila (5%). The most frequent
causes of treatment inadequacy were use of b-lactams
alone (25%) and lack of aspiration assessment (15%).
Prognostic factors of 1-month mortality were
neurological comorbidities (OR 4.5; 95% CI 1.3 to 15.7;
p¼0.020), septic shock (OR 6.6; 95% CI 1.3 to 34.0;
p¼0.025), pleural effusion (OR 3.6; 95% CI 1.1 to 11.7;
p¼0.036) and isolation of GNB or MRSA (OR 16.4; 95%
CI 2.1 to 128.9; p¼0.008).
Conclusions The patients show clinical characteristics
(eg, age and co-morbidities) comparable with those with
hospital-acquired pneumonia. However, microbiological
and mortality data of patients with NHAP are more
similar to the data of those with CAP. Isolation of GNB or
MRSA was associated with increased mortality risk. CAP
empirical antibiotic coverage is still indicated in NHAP,
although specific risk factors for multidrug-resistant
infections should be assessed on an individual basis.
INTRODUCTION
Nursing home-acquired pneumonia (NHAP) is
probably the largest subgroup of healthcare-associ-
ated pneumonia (HCAP), and the number of cases
has increased in recent decades, with the worldwide
diffusion of long-term care facilities (LTCFs).1
Moreover, the number of older individuals living in
nursing homes (NHs) is expected to increase
dramatically in the next 30 years, as 40% of adults
will probably reside in an LTCF in later life.2
Pneumonia is the second most common infection
in NH and the leading cause of mortality and
hospitalisation.3e7 Much information has been
gathered on NHAP since the 1970s6e8: patients
with NHAP are usually elderly, with multiple
diseases (eg, cardiovascular, respiratory and neuro-
logical) and poor functional status.9e11 The clinical
presentation of NHAP is often unusual,6 7 9 12 13
with frequent extrapulmonary manifestations
(mental confusion and gastrointestinal disorders),14
and the clinical presentation may be worse than in
community-acquired pneumonia (CAP) (eg, hypo-
xaemia and altered consciousness).11 15 16 The
mortality rate of NHAP is close to that of hospital-
acquired pneumonia (HAP)7 9 11 15e17 (20e40%),
while its annual incidence is 30-fold that of the
general population and 11-fold that for the elderly
($75 years).4 7 18 19
A major concern has emerged regarding the
microbial aetiology of NHAP, since two large
retrospective studies on HCAP have reported an
elevated incidence of pathogens common in
nosocomial infections (Gram negative bacilli
(GNB), or methicillin-resistant Staphylococcus
aureus (MRSA))10 20 and, particularly, of multi-
drug-resistant (MDR) microorganisms,21 22 which
may justify nosocomial antibiotic coverage on
admission.1
In contrast, two prospective European studies
described Streptococcus pneumoniae and Haemophilus
influenzae as the most frequent pathogens in
NHAP.9 11 17
Therefore, the microbial aetiology of NHAP is
still under debate, while the effect of comorbidities,
functional status, abnormal clinical presentation
and microbial aetiology on the high mortality of
HCAP is unclear.
The first objective of our study was to investi-
gate microbial aetiology in NHAP and, particularly,
the frequency of MDR microorganisms. Hence, the
adequacy of empirical antibiotic therapy in our
hospital was also investigated in order to review the
current antibiotic treatment recommendations.
Secondly, we analysed possible risk factors for
MDR infections, such as demographic, clinical and
biochemical data, and severity scores.
Lastly, we investigated possible prognostic
factors of mortality, including demographic, clinical
and biochemical data on admission, and microbial
aetiology.
MATERIALS AND METHODS
Study population
We prospectively studied all consecutive cases of
NHAP admitted to Hospital Clinic, Barcelona,
Spain, from 1 February 1997 to 1 July 2007.
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In Spain, NH are currently considered institutions dedicated
to assist individuals unable to perform routine daily activities
autonomously, including toileting, eating and mobility. NH
assistance usually includes part-time medical and physiotherapy
support and full-time nursing care.
The diagnosis of pneumonia was made by the Emergency
department (ED) doctor and confirmed by the respiratory
physician in charge of recruitment and data collection for the
study. The choice of empirical antibiotic treatment was taken
exclusively by the attending physician. Immunosuppressed patients
(neoplasia, severe haematological disorders, HIV, immunosuppres-
sant treatment, chemotherapy in the last year) were excluded.
Data collection
Demographic data, comorbid illness (eg, chronic cardiovascular
diseases, diabetes mellitus, chronic liver disease, renal failure,
dementia and neurological diseases), previous antibiotic treat-
ment and relevant data from the clinical history (eg, use of
inhaled/systemic corticosteroids, influenza and pneumococcal
vaccinations, smoking, alcohol intake, previous pneumonia,
aspiration evidence and antibiotic allergies) were recorded in an
Access database. Neurological disorders include degenerative
diseases, multiple sclerosis, amyotrophic lateral sclerosis,
Parkinson disease, Down syndrome, stroke and postanoxia brain
injury. Autonomy for routine daily activities, including toileting,
eating and mobility, was classified as follows: total (no need for
external help), partial (need for partial help) and none (totally
dependent on external help).
The following parameters were also recorded on admission: days
of clinical course before admission, time elapsed in ED, clinical
symptoms, vital signs, laboratory data, chest x-ray (number of
affected lobes, infiltrate radiographic pattern and localisation,
presence of pleural effusion/atelectasis/cavitations), and PSI
(Pneumonia Severity Index) and CRB-65 (confusion, respiratory
rate, low blood pressure, age $65 years) prognostic scales.
Relevant data on clinical course were recorded, including
treatment (antibiotics and systemic corticosteroids, time of first
doses from admission, compliance with the American guidelines
for CAP management23), length of hospital stay, oxygen (arterial
oxygen pressure (PaO2)/fractional inspired oxygen (FiO2)) and
ventilatory support (mechanical ventilation, non-invasive
ventilation), day of clinical stability according to American
Thoracic Society (ATS)/Infectious Diseases Society of America
(IDSA) criteria,23 pulmonary (empyema, respiratory distress,
pleural parapneumonic effusion, pneumothorax, surgical pleural
draining) and extrapulmonary complications (cardiac arrhyth-
mias, septic shock, acute renal failure, meningitis, endocarditis,
SIADH (syndrome of inappropriate antidiuretic hormone
secretion), positive/negative Clostridium diarrhoea, antibiotic
secondary effects), in-hospital and 1-month mortality rates and
cause of death, and treatment failure.23
We considered the treatment prescribed during the first 24 h of
hospitalisation to be the initial treatment. An antibiotic regimen
was defined as ATS adherent when the chosen antibiotics
followed the recommendations included in the 2007 ATS
guidelines, regardless of any additional antibiotic received.23
Appropriate first-line CAP antibiotic treatments were consid-
ered to be b-lactam+macrolide or a quinolone alone. Where
aspiration was suspected, amoxicillineclavulanic acid or piperacilline
tazobactam was considered appropriate antibiotic treatment.
Microbiological data
Within the first 24e48 h after admission, regular samples of
sputum, blood for two cultures and serum for paired serology
were taken (on admission and 4e6 weeks thereafter) for atypical
pathogens (Chlamydia pneumoniae, Mycoplasma pneumoniae,
Coxiella burnetii) and respiratory viruses. Tests for detection of
urinary antigens for Legionella pneumophila and S pneumoniae
were systematically performed.
Respiratory secretion samples, including spontaneous sputum
or bronchoalveolar lavage (BAL) fluid, fibreoptic bronchial aspi-
rates (FBAS), tracheobronchial aspirates (TBAS) and pleural
fluid, when available, were collected for Gram and Ziehle
Nielsen stains and for cultures for bacterial, fungal and myco-
bacterial pathogens.
Sample processing
Sample processing techniques are described in previous studies
by our group.24
Diagnostic criteria
The aetiology of pneumonia was classified as presumptive if
a valid sputum sample yielded $1 predominant bacterial strains.
Aetiology was considered definite if one of the following criteria
was met: (1) blood cultures yielding a bacterial or fungal path-
ogen (in the absence of an apparent extrapulmonary focus); (2)
pleural fluid cultures yielding a bacterial pathogen; (3) serocon-
version (ie, a fourfold increase in immunoglobulin G (IgG) titres)
for C pneumoniae and L pneumophila >1:128, C burnetii >1:80,
and respiratory viruses (ie, influenza viruses A and B, para-
influenza viruses 1e3, respiratory syncytial virus, adenovirus);
(4) a positive urinary antigen for L pneumophila or S pneumoniae;
and (5) bacterial growth in cultures of TBAS or FBAS >105 cfu/
ml and in BAL >104 cfu/ml. A diagnosis of probable aspiration
was made in cases of witnessed aspiration or in the presence of
risk factors for aspiration (severely altered consciousness,
abnormal swallowing).
We considered an uncommon microbial aetiology for CAP
when GNB (ie, Escherichia coli, Klebsiella pneumoniae, etc), Pseu-
domonas aeruginosa or MRSA were isolated.
STATISTICS
Categorical variables were described using counts and percent-
ages. Continuous variables were expressed as the mean6SD, or
median and IQR for abnormally distributed data (Kolmogor-
oveSmirnov test). Relationships between categorical variables
were studied using the c2 test, or Fisher exact test, when
necessary. Comparison of continuous variables between two
groups was carried out using the t test for unpaired data once
normality was demonstrated; otherwise, the non-parametric
test (ManneWhitney U test) was used. Univariate and multi-
variate logistic regression analyses were conducted to identify
variables predictive of patients with potential first-line CAP
antibiotic-resistant microorganisms (GNB or MRSA) (dependent
variable). The independent variables were age, sex, length of
stay, pneumonia in the previous year, suspected aspiration,
inhaled corticosteroids, heart failure, chronic renal failure, dia-
betes mellitus, chronic liver disease, neurological disorders,
chronic respiratory diseases, smoking, alcohol, autonomy for
daily activities, pneumococcal vaccination, influenza vaccina-
tion, systemic corticosteroids, fever, dyspnoea, acute renal
failure, shock, PCR, leucocytes >123109/l, PaO2/FiO2 <200,
cavitation, atelectasis, pleural effusion, more than two affected
lobes, PSI score and CRB-65 classes. Univariate and multivariate
logistic regression analyses were performed to predict 30-day
mortality (dependent variable). Independent variables were as
above, including possible first-line CAP antibiotic-resistant
Thorax 2010;65:354e359. doi:10.1136/thx.2009.124776 355
Respiratory infection
 o
n
 N
ovem
ber 1, 2019 by guest. Protected by copyright.
http://thorax.bmj.com/
Thorax: first published as 10.1136/thx.2009.124776 on 13 April 2010. Downloaded from
 
microorganisms (GNB or MRSA). Variables that showed
a significance in the univariate analysis (p<0.1) were included in
the multivariate logistic regression backward stepwise model to
determine which of them were independently related to
outcome. The HosmereLemeshow goodness-of-fit test was
performed to assess the overall fit of the model. All analyses
were performed using SPSS 16 for Windows; a two-tailed p value
of <0.05 was considered statistically significant.
RESULTS
Study population
We analysed 150 consecutive cases of NHAP (median age
82 years (77e87 years); males, 49%); Table 1 shows the main
characteristics.
Median length of stay was 8 days (5e13 days). Only 20
patients (13%) were admitted to the intensive care unit (ICU);
their median length of stay was 11 days (9e23 days). Tables 2
and 3 show data on clinical presentation on admission (symp-
toms, analytical data and radiographic patterns) and severity
indexes, respectively. NHAP were mainly classified as mild to
moderate according to the CRB-65 score (CRB-65 classes 0e1
and 2, 41% each) but as moderate to severe by the Fine score
(Fine classes 4 and 5, 33% and 53%) due to the weight of age in
the PSI calculation.
In-hospital mortality was 8.7% (n¼13) globally and 20%
(n¼30) after 1 month. Deceased patients had been mainly
hospitalised in a ward (n¼23; 77%); only five (17%) were in an
ICU. The most frequent respiratory complication was empyema
(n¼5), followed by acute respiratory distress syndrome (n¼2)
and pleural effusion (n¼2). Extrapulmonary complications
included renal failure in nine cases (9%), cardiac arrhythmia in
six (6%) and septic shock in five (5%). Clinical stability was
reached after a median of 6 days (4e9 days) of hospitalisation.
Aetiology was defined in 38% of cases (n¼57) (table 4).
The most common isolates were S pneumoniae (58%) and
Enterobacteriaceae (E coli and K pneumoniae) (9%). L pneumophila,
respiratory virus and MRSA were isolated in three cases each
(5%). Mixed aetiology was detected in four patients, including
two cases of S pneumoniae and a respiratory virus, one of E coli
and C pneumoniae, and one of MRSA and K pneumoniae. H
influenzae was isolated in only two patients (4%).
An antibiotic resistance pattern was available in 32 patients,
including 22 cases of S pneumoniae, 3 MRSA, 1 P aeruginosa, 2 E
coli, 1 K pneumoniae, 2 H influenzae and 1 Providencia stuartii.
Microbial aetiology in deceased patients was determined in
only 10 cases (33%) and did not differ significantly from that of
survivors, since S pneumoniae was the most frequently isolated
microorganism (n¼5; 50%) followed by GNB (2 cases of K
pneumoniae, 1 E coli and 1 P stuartii) and MRSA (n¼1).
Initial antibiotic treatment was aimed at CAP coverage,
except for six patients who received a broad-spectrum antibiotic
(ie, carbapenem), and included combined b-lactam+quinolone
(30%), b-lactam alone (25%), quinolone alone (17%) and
combined b-lactam+macrolide (11%). Accordingly, the most
frequent causes of empiric antibiotic inadequacy were the use of
b-lactams alone and lack of aspiration assessment in 25% and
15% of cases, respectively.
Table 1 Main characteristics of the study population,
n (%)*
Smoking habit
Non-smokers 83 (66)
Smokers 12 (10)
Ex-smokers 31 (25)
Vaccinations
Pneumococcal vaccination 15 (15)
Influenza vaccination 75 (75)
Autonomy for daily activities
Full 36 (31)
Partial 38 (32)
Previous pneumonia in the last year 23 (18)
Inhaled corticosteroids 25 (19)
Systemic corticosteroids 4 (3)
Co-morbidities
Heart failure 47 (35)
Chronic renal failure 10 (8)
Diabetes mellitus 28 (21)
Chronic liver disease 3 (2)
Neurological disorders 73 (55)
Chronic respiratory diseases 51 (38)
Chronic respiratory diseases include: asthma (4%), chronic bronchitis
(9%), chronic obstructive pulmonary disease (14%), ex tuberculosis
sequelae (4%), pulmonary hypertension (1%) and others (4%).
Neurological disorders include: degenerative diseases, multiple sclerosis,
amyotrophic lateral sclerosis, Parkinson disease, Down syndrome,
vascular cerebral accidents, postanoxia brain injury and dementia.
*Percentages of all cases with available information.
Table 2 Clinical presentation and laboratory data on
admission
Symptoms, n (%)*
Previous ‘common cold’ symptoms 49 (38)
Fever 106 (79)
Chills 46 (36)
Cough 107 (80)
Purulent phlegm 66 (50)
Pleuritic pain 33 (25)
Dyspnoea 102 (76)
Nausea/vomiting 12 (12)
Altered mental status 67 (50)
Acute renal failure 22 (17)
Shock 14 (10)
Radiographic features
Cavitation 1 (1)
Atelectasis 8 (6)
Pleural effusion 27 (20)
Alveolar infiltrate pattern 119 (77)
Interstitial infiltrate pattern 1 (1)
Mixed infiltrate pattern 3 (2)
Number of affected lobes, 1 83 (61)
Number of affected lobes, $2 51 (38)
Vital signs, mean±SD
Respiratory rate 2967
Heart rate 96619
Systolic blood pressure, mm Hg 129628
Diastolic blood pressure, mm Hg 69614
Analytical data
Leucocytes >123109/l, n (%) 76 (56)
Creatinine, mg/dl 1.562.0
C-reactive protein, mg/dl 20613
Platelets, 3103/l 2776111
Na, mEq/l 13867
K, mEq/l 4.260.7
Haematocrit, % 3866
Serum proteins, g/l 6066
Albumin, g/l 3367
*Percentages of all cases with available information.
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With regard to antibiotic resistance, we observed that initial
antibiotic therapy was inappropriate in 12 patients (38%); the
antibiotic was changed on admission but there were no signifi-
cant changes in mortality (only three patients with initial
inadequate antibiotic therapy died during hospitalisation).
Microbial aetiology
Demographic, clinical and biochemical variables were compared
for patients with typical CAP microbiology (ie, S pneumoniae, H
influenzae, etc) (n¼47) and those with potential first-line CAP
antibiotic-resistant microorganisms (GNB or MRSA) (n¼11). No
statistically significant differences were found between the two
groups except for PSI score (132.6625.3 for patients with typical
CAP vs 157.7630.0 for patients with GNB or MRSA; t test;
p¼0.014) and CRB-65, which was higher in patients with GNB
or MRSA (classes 3e5: 13% for patients with typical CAP vs
54% for patients with GNB or MRSA; c2; p¼0.007). Statistically
significant variables in the univariate analysis were PSI scoring
(+1 point increase; OR 1.04; 95% CI 1.01 to 1.07; p¼0.024),
CRB-65 classes 3e5 (OR 12.5; 95% CI 2.0 to 78.0; p¼0.007) and
length of stay (+1 day increase; OR 1.08; 95% CI 0.99 to 1.17;
p¼0.075). No independent predictors of GNB or MRSA were
found in the multivariate analysis.
One-month mortality
Demographic, clinical and biochemical variables were compared
between patients who were deceased at 1 month (n¼30) and
survivors. No significant differences were found between the
two groups except for neurological co-morbidities (76% for
patients who had died at 1 month vs 49% for survivors; c2;
p¼0.023), and autonomy for daily activities (full: 6% for
patients who died at 1 month vs 37% for survivors; c2;
p¼0.023). In the multivariate analysis (table 5), the independent
predictors of 1-month mortality were neurological diseases (OR
4.5; 95% CI 1.3 to 15.7; p¼0.020), septic shock (OR 6.6; 95% CI
1.3 to 34.0; p¼0.025), pleural effusion (OR 3.6; 95% CI 1.1 to
11.7; p¼0.036) and isolation of GNB or MRSA (OR 16.4; 95% CI
2.1 to 128.9; p¼0.008) (table 5).
The c2 goodness-of-fit analysis demonstrated the model’s
adequacy (p>0.05).
DISCUSSION
The peculiarities of NH populations and the increased risk of
mortality have led NHAP to be considered a separate clinical
entity, thereby justifying specific recommendations for clinical
management25e27 and, recently, inclusion among HCAP.1 As
in the literature, our population showed advanced age,
numerous comorbidities (particularly neurological disorders),
poor autonomy for daily activities (up to 70% of patients were
partially or totally dependent) and, frequently, atypical clinical
presentation (extrapulmonary manifestations). The role of age,
comorbidities and functional status in this population thus
appears to have a considerable effect on pneumonia severity and
mortality.28 Many authors have shown that patients’ functional
status before admission is one of the most important prognostic
factors for mortality6 29e32 and may considerably influence the
decision of site of care (NH vs hospital, ICU admission, etc) and
aspects of clinical management (diagnostic procedures and life-
prolonging treatments).7 26 33 34 We also observed that a history
of neurological disorders (a major cause of the inability to
perform daily activities) was an important prognostic factor of
mortality. The highest mortality rate was recorded among
Table 4 Bacteriological findings of 57 nursing home patients (38% of total population) with either probable or definitive aetiology of a pneumonia
episode
n (%) Sputum Blood TBAS, BAL Pleural fluid Serology Urinary antigen N-P swab
S pneumoniae 33 (22) 9 6 3 4 19
H influenzae 2 (1) 2 0 1 0
MRSA 3 (2) 2 1 1 0
P aeruginosa 2 (1) 2 0 0 0
K pneumoniae 2 (1) 0 1 2 0
E coli 3 (2) 0 1 2 1
C pneumoniae 1 (1) 2
M pneumoniae 2 (1) 2
C burnetii 1 (1) 1
L pneumophila 3 (2) 0 0 0 0 3
Virus 3 (2) 3 2
P stuartii 1 (1) 1
Candida albicans 1 (1) 1 0 1 0
Total 57 (38) 17 9 10 5 8 22 2
Note: percentages refer to the total number of patients (n¼150).
BAL, bronchioalveolar lavage; MRSA, methicillin-resistant Staphylococcus aureus; N-P swab, naso-pharyngeal swab; TBAS, tracheobronchial aspirate.
Table 3 Severity indices
n (%)*
Acute respiratory failure
PaO2/FiO2 <200 16 (16)
Basal SatO2 <92% 61 (54)
Acute renal failure (creatinine >1.5 mg/dl) 28 (21)
Shock 14 (10)
Multilobar infiltration 51 (38)
2 lobes affected 42 (31)
$3 lobes affected 9 (7)
Admission to ICU 13 (9)
Admission to intermediate care unit 7 (5)
Fine score, 1e2 9 (6)
Fine score, 3 12 (8)
Fine score, 4e5 129 (86)
CRB-65 score, 0e1 61 (41)
CRB-65 score, 2 61 (41)
CRB-65 score, 3e4 28 (19)
Pneumonia severity index (PSI), mean6SD 137628
*Percentages of all cases with available information.
CRB-65, pneumonia severity score including: consciousness,
respiratory rate, blood pressure, 65 years of age cut-off; ICU, intensive
care unit.
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patients admitted to the ward, suggesting that functional
status, premorbid condition and, possibly, ethical considerations
limited ICU admission of patients with poor life expectancy.
The mortality rate of our population (8%) was very similar
to14 35 or lower36 than that reported for CAP in the general
population and in the elderly. In contrast, many studies on
NHAP9 11 28 and the recent North American series on HCAP
report higher mortality rates (up to 40%).15 16 Interestingly, the
Spanish study by Carratalà on HCAP, including 32 NH patients
(25.4% of all HCAP), shows a mortality rate very close to that of
this study (10.3% for HCAP and 4% for CAP).17 This similarity
suggests two considerations: first, the considerable differences
among these studies may denote a geographic variation of
pathogens, virulence and antibiotic resistances. Secondly, no
unique definition of NH is currently available worldwide and it
may not be possible given the organisational differences in local
healthcare systems and LTCFs in different countries. Therefore,
both the geographic distribution of pathogens and differences in
NH populations from different countries may partly explain
such remarkable differences in mortality.
A central issue regarding NHAP and HCAP is microbial aeti-
ology and, consequently, the empirical antibiotic treatment to
use in clinical practice. Before guidelines for HAP, ventilator-
associated pneumonia (VAP) and HCAP, published in 2005,1
recommendations for NHAP antibiotic treatment closely
resembled CAP guidelines.23 37 Since the North American
studies15 16 reported a very high incidence of MDR infections
among HCAP, an intense debate arose on the microbial aetiology
of NHAP. Subsequently, American guidelines suggested empiri-
cally treating HCAP as a nosocomial infection.1
However, analysing the American retrospective studies on
HCAP,15 16 it is clear that the high rates of ICU admission,
ventilatory support and mortality (pneumonia severity), the
high incidence of GNB, even in patients with CAP, and the
scarce information on microbiological methods make these data
poorly comparable with ours.
The literature shows that, with the exception of two Amer-
ican studies on elderly patients with severe NHAP,10 11 no other
studies confirm the hypothesis of a nosocomial pattern in NHAP
and HCAP.9 11 17 Venditti et al38 show that receiving empirical
antibiotic treatment not recommended by the latest HCAP
guidelines was independently associated with increased
mortality. Surprisingly, no microbiological data are shown in
that study, suggesting that clinical conditions before hospital-
isation, comorbidities or any other possible confounding factor
may explain these results.
This is one of the largest NHAP series of the last decade and
clearly shows that, in Spain, S pneumoniae is still the most
frequent organism causing pneumonia. Unfortunately, the rate
of positive microbiological findings is fairly low, but similar to
many other series of NHAP7 for different reasons, such as the
following: (1) a poor cough reflex and an altered mental status
considerably reduce availability of sputum samples in NH
patients; (2) blood cultures are usually performed only in
patients with fever, and elderly patients commonly have fewer
temperature alterations in response to infection than younger
individuals; and (3) pneumococcal and L pneumophila urinary
antigens are the most common source of aetiological diagnosis
but were introduced only in late 2000. Some infrequent bacteria,
such as P aeruginosa and MRSA, can be easily detected even in
poor-quality biological samples (ie, sputum), thereby increasing
the number of cases with known aetiology.
It is also worth noting that empirical treatment was mainly
concordant with CAP guidelines23 and, depending on antibiotic
resistance, was inappropriate only in a few cases, with no
increased mortality. Moreover, the microbial pattern did not
differ between survivors and deceased patients, showing that
the effect of aetiology on mortality in our series is probably
slight.
However, it is important to underline that isolation of
unusual microorganisms such as GNB or MRSA (potentially not
susceptible to first-line CAP antibiotic treatment), which are
more frequent in patients with higher severity scores, was
associated with a considerable increase in the mortality risk.
Therefore, we still need to be cautious with therapeutic
recommendations: a careful evaluation of possible risk factors
for MDR infections in patients with NHAP, such as previous
antibiotic treatment, recent hospitalisation or advanced chronic
respiratory disease (ie, bronchiectasis or chronic obstructive
pulmonary disease) and functional status before admission,
appears essential to guide the use of broad-spectrum antibiotics
on an individual basis.31 Moreover, functional status before
admission should always be investigated in the process to decide
diagnostic procedures and site of care.
Table 5 Analysis of prognostic factors of 1-month mortality: significant univariate and multivariate
associations
Univariate analysis Multivariate analysis
OR 95% CI p Value OR 95% CI p Value
Autonomy for daily activities 0.078
Full 1.0 e e
Partial 8.7 1.0 to 75.3 0.050
None 11.5 1.4 to 95.6 0.024
Neurological diseases 3.3 1.1 to 9.9 0.029 4.5 1.2 to 15.7 0.020
Septic shock 3.0 0.9 to 10.1 0.078 6.6 1.2 to 34.0 0.025
Pleural effusion 2.7 0.9 to 7.9 0.063 3.6 1.1 to 11.7 0.036
Pathogens 0.036 0.028
Typical CAP 1.0 e e 1.0 e e
GNB+MRSA 6.5 1.4 to 29.4 0.015 16.4 2.1 to 128.9 0.008
Unknown aetiology 3.0 1.0 to 8.7 0.043 3.0 0.6 to 14.4 0.165
PSI scoring, +1 point 1.02 1.01 to 1.05 0.029
Typical CAP pathogens include: S pneumoniae, H influenzae, L pneumophila, M pneumoniae, C burnetii, C pneumoniae. GNB include:
P aeruginosa, E coli, K pneumoniae, P stuartii. Neurological disorders include: degenerative diseases, multiple sclerosis, amyotrophic
lateral sclerosis, Parkinson disease, Down syndrome, vascular cerebral accidents, postanoxia brain injury and dementia.
CAP, community-acquired pneumonia; GNB, Gram-negative bacilli; MRSA, methicillin-resistant Staphylococcus aureus; PSI, pneumonia
severity index; ‘+1 point’ indicates a PSI increase of one point.
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The following are possible limitations of this study:
1. The introduction of the urinary antigen detection method for
S pneumoniae and for L pneumophila only in 2000 may have
influenced the rate of aetiological findings in the first 3 years
of this series.
2. The initial study design did not consider a caseecontrol
match with patients with CAP that might have comple-
mented clinical and microbiological information on NHAP.
3. This is a single-centre Spanish study and our data may not be
representative of Europe.
In conclusion, our NH patients appeared more similar to
those affected by HAP in terms of age, functional status
and comorbidities; however, low mortality was recorded. A
‘community ’ microbial pattern was observed in NHAP, with the
only exception of Enterobacteriaceae being slightly more
frequent than in CAP. Additionally, isolation of GNB and MRSA
was associated with a considerable increase in mortality risk.
These findings suggest that ‘community-based’ empirical
antibiotic treatment is still indicated in NHAP, but additional
risk factors for MDR infections (eg, previous antibiotic treat-
ment and recent hospitalisation) and the risk of aspiration
should always be assessed on an individual basis in order to
guide the selection of broad-spectrum antibiotic treatment.
Further investigation with sound microbiological method-
ology is needed in NHAP to properly evaluate risk factors for
MDR infections and optimise empirical antibiotic therapy.
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